Announcements Trials
Browse Landscape

Status

Recruiting 3Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 74Observational 5Expanded_access 1

Sponsor

Cancer Type

Dermatologic 3Head & Neck 1

Conditions

Melanoma 3Thyroid Neoplasms 1Skin Neoplasms 1Recurrence 1

Interventions

Blood Specimen Collection 131Surveys and Questionnaires 130Specimen Handling 57Observation 55Radiotherapy 44Interviews as Topic 34Surgical Procedures, Operative 32Drug Therapy 31Biopsy 28Data Collection 26Magnetic Resonance Spectroscopy 25Nivolumab 20Watchful Waiting 20Immune Checkpoint Inhibitors 18Immunotherapy 17Magnetic Resonance Imaging 17Therapeutics 17Standard of Care 16trastuzumab deruxtecan 14Liquid Biopsy 13Tomography, X-Ray Computed 13palbociclib 13Hematologic Tests 12Restraint, Physical 12Focus Groups 11Genetic Testing 11Bevacizumab 10Positron Emission Tomography Computed Tomography 10darolutamide 10enzalutamide 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Observational × trametinib × 1 year × Clear all
NCT04666272 2026-02-19

Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection

Novartis

Active not recruiting
78 enrolled
Dermatologic

Melanoma

NCT07419932 2026-02-19

NeoLATC

Fujian Medical University

Recruiting
120 enrolled
Head & Neck

Thyroid Neoplasms

NCT06262919 2025-12-30

Special Drug Use-results Surveillance of Tafinlar/Mekinist

Novartis

Recruiting
110 enrolled

Recurrence

NCT04961619 2025-12-12

LEAD Melanoma

Novartis

Completed
39 enrolled
Dermatologic

Melanoma

NCT07092670 2025-09-05

MELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse.

Intergruppo Melanoma Italiano

Recruiting
270 enrolled
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡